Alignment reached on key elements of ATH434 Phase 3 development programMELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results